Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

miR-34a directly targets tRNAiMet precursors and affects cellular proliferation, cell cycle, and apoptosis.

Wang B, Li D, Kovalchuk I, Apel IJ, Chinnaiyan AM, Wóycicki RK, Cantor CR, Kovalchuk O.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7392-7397. doi: 10.1073/pnas.1703029115. Epub 2018 Jun 25.

2.

EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.

Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY, Asangani IA.

Cancer Res. 2018 Aug 15;78(16):4760-4773. doi: 10.1158/0008-5472.CAN-18-0484. Epub 2018 Jun 13.

PMID:
29898995
3.

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM.

Cancer Cell. 2017 Jun 12;31(6):844-847. doi: 10.1016/j.ccell.2017.05.001. No abstract available.

4.

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM.

Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub 2017 Mar 23. Erratum in: Cancer Cell. 2017 Jun 12;31(6):844-847.

5.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

6.

Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.

Markó L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Müller DN.

Hypertension. 2014 Nov;64(5):1032-9. doi: 10.1161/HYPERTENSIONAHA.114.03900. Epub 2014 Sep 2.

7.

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.

8.

Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.

Van Beek M, Oravecz-Wilson KI, Delekta PC, Gu S, Li X, Jin X, Apel IJ, Konkle KS, Feng Y, Teitelbaum DH, Ruland J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2012 May 31;1(5):444-52.

9.

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.

10.

Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.

Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC.

J Biol Chem. 2010 Dec 31;285(53):41432-42. doi: 10.1074/jbc.M110.158949. Epub 2010 Nov 1.

11.

Interaction of retinal bZIP transcription factor NRL with Flt3-interacting zinc-finger protein Fiz1: possible role of Fiz1 as a transcriptional repressor.

Mitton KP, Swain PK, Khanna H, Dowd M, Apel IJ, Swaroop A.

Hum Mol Genet. 2003 Feb 15;12(4):365-73.

PMID:
12566383
12.

Multiple phosphorylated isoforms of NRL are expressed in rod photoreceptors.

Swain PK, Hicks D, Mears AJ, Apel IJ, Smith JE, John SK, Hendrickson A, Milam AH, Swaroop A.

J Biol Chem. 2001 Sep 28;276(39):36824-30. Epub 2001 Jul 27.

13.
14.

Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins.

Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ.

Cell. 1998 Oct 30;95(3):365-77.

15.

A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells.

Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, González-García M, Doedens M, Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Núñez G.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11024-8.

16.

Bcl-XL protects cancer cells from p53-mediated apoptosis.

Schott AF, Apel IJ, Nuñez G, Clarke MF.

Oncogene. 1995 Oct 5;11(7):1389-94.

PMID:
7478561
17.

c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle.

Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nuñez G, Clarke MF.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5878-82.

Supplemental Content

Support Center